Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Windtree Therapeutics Inc is a biotechnology business based in the US. Windtree Therapeutics shares (WINT) are listed on the NASDAQ and all prices are listed in US Dollars. Windtree Therapeutics employs 31 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$2.01|
|52-week range||$1.58 - $7.53|
|50-day moving average||$2.00|
|200-day moving average||$2.04|
|Wall St. target price||$10.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.23|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-11.84%|
|1 month (2021-09-21)||3.61%|
|3 months (2021-07-21)||5.79%|
|6 months (2021-04-21)||-6.94%|
|1 year (2020-10-21)||-73.09%|
|2 years (2019-10-21)||-35.16%|
|3 years (2018-10-18)||2.88|
|5 years (2016-10-21)||2.85|
|Gross profit TTM||$-15,373,000|
|Return on assets TTM||-17.93%|
|Return on equity TTM||-89.61%|
|Market capitalisation||$60.9 million|
TTM: trailing 12 months
There are currently 1.0 million Windtree Therapeutics shares held short by investors – that's known as Windtree Therapeutics's "short interest". This figure is 18.2% down from 1.2 million last month.
There are a few different ways that this level of interest in shorting Windtree Therapeutics shares can be evaluated.
Windtree Therapeutics's "short interest ratio" (SIR) is the quantity of Windtree Therapeutics shares currently shorted divided by the average quantity of Windtree Therapeutics shares traded daily (recently around 296713.74269006). Windtree Therapeutics's SIR currently stands at 3.42. In other words for every 100,000 Windtree Therapeutics shares traded daily on the market, roughly 3420 shares are currently held short.
However Windtree Therapeutics's short interest can also be evaluated against the total number of Windtree Therapeutics shares, or, against the total number of tradable Windtree Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Windtree Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Windtree Therapeutics shares in existence, roughly 40 shares are currently held short) or 0.072% of the tradable shares (for every 100,000 tradable Windtree Therapeutics shares, roughly 72 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Windtree Therapeutics.
Find out more about how you can short Windtree Therapeutics stock.
We're not expecting Windtree Therapeutics to pay a dividend over the next 12 months.
Windtree Therapeutics's shares were split on a 1:3 basis on 28 April 2020. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Windtree Therapeutics shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Windtree Therapeutics shares which in turn could have impacted Windtree Therapeutics's share price.
Over the last 12 months, Windtree Therapeutics's shares have ranged in value from as little as $1.58 up to $7.525. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Windtree Therapeutics's is -0.0746. This would suggest that Windtree Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Windtree Therapeutics has bucked the trend.
Windtree Therapeutics, Inc. , a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company has a collaboration with University of Milan-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.